ACE inhibitory i sartany a przebieg COVID-19 -metaanaliza u blisko 30 tysięcy chorych

Baral, R. i wsp.  Effect of Renin-Angiotensin-Aldosterone System Inhibitors in Patients with COVID-19: a Systematic Review and Meta-analysis of 28,872 Patients. Curr Atheroscler Rep 2020;22,61  (dostępny pełen tekst)

This is the largest meta-analysis including critical events and mortality data on patients prescribed ACEi/ARB and found evidence of beneficial effects of chronic ACEi/ARB use especially in hypertensive cohort with COVID-19. As such, we would strongly encourage patients to continue with RAAS inhibitor pharmacotherapy during the COVID-19 pandemic

Current Atherosclerosis Reports, 24 sierpnia 2020

Dodaj komentarz